Company: VEEV
Filing Date: 2025-05-05
Form Type: DEF 14A
Source: 0001140361-25-017353
Chunk: 35

Company: VEEVA SYSTEMS INC
Filing Date: 2025-05-05
Form: DEF 14A
Chunk 35
---
 or more logins for a single study, a distinct inefficiency solved byVeevaID. Over 30,000 users have registered for aVeevaID. |

| • | We continue to operate clinicaltrials.veeva (CTV), a free website that gives patients, sites, and sponsors a better way to find clinical trials. Though still relatively new, CTV had over 1 million visitors last year, has over 100,000 unique visitors each month, and has thousands of visitors signed up to stay informed about studies. |

| • | Veeva ePRO—used by patients in clinical trials—continues to grow rapidly, today serving more than four times the sites and patients as compared to a year ago.Veeva ePROhas live studies across all clinical trial phases, including large global trials. Customers useVeeva ePROto make the clinical trial experience much easier for patients with this simple mobile application. This eases the technology and education burden on clinical trial participants and helps enable faster study builds. |

| Veeva Systems Inc. | 2025 Proxy Statement37 |

TABLE OF CONTENTS

Our Public Benefit Corporation Report

| • | Objective 2: Support customer choice and remove competitive barriers from the industry |

| • | Life sciences companies should have the freedom to choose the software, data products, and services that meet their business needs without undue restrictions. Choice benefits the life sciences industry and is crucial for the industry to fulfill its mission of improving the lives of patients. Today we maintain more than 800 agreements that allow third parties (often competitors) to access our proprietary data and cloud software products for that purpose. We do not block or disable integrations to third-party software products. Instead, we enable them through open APIs where possible. We have also taken legal action against IQVIA to stop their anti-competitive practices that we believe harm the life sciences industry and violate antitrust laws. |

Additionally, in January 2024 we announced the availability of the full Veeva Compasssuite of commercial data products to provide the industry a better alternative to IQVIA, the historically dominant provider. Compassuniquely supports the needs of today’s modern medicines because it gives brands unlimited data access, projects data for both retail prescriptions and complex procedures, and is licensed by the brand. Veeva Public Benefit Purpose (Part 2): Creating high-quality employment opportunities.

| • | Objective 3: High-Quality Job Creation — continue to create high-quality employment opportunities for the long